Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EAGLE PHARMACEUTICALS, INC.

(EGRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eagle Pharmaceuticals : Granted Additional Patent for Leukemia Medication Bendamustine

08/31/2021 | 07:32am EDT


© MT Newswires 2021
All news about EAGLE PHARMACEUTICALS, INC.
10/14EAGLE PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial Statements..
AQ
10/01EAGLE PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/01Eagle Pharmaceuticals, Inc. Announces Executive Changes
CI
09/09EAGLE PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
09/07REMINDER : Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
BU
09/01EAGLE PHARMACEUTICALS : to Present at September Healthcare Conferences
BU
09/01ENDO INTERNATIONAL : Comments on Non-Infringement Ruling in VASOSTRICT Patent Litigation
AQ
08/31EAGLE PHARMACEUTICALS : Says Court Rules in Favor of Proposed Vasopressin Product in Paten..
MT
08/31EAGLE PHARMACEUTICALS : Wins Vasopressin Patent Trial (Form 8-K)
PU
08/31Eagle Pharmaceuticals, Inc. Wins Vasopressin Patent Trial
CI
More news
Analyst Recommendations on EAGLE PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 189 M - -
Net income 2021 -0,23 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2 615x
Yield 2021 -
Capitalization 685 M 685 M -
Capi. / Sales 2021 3,63x
Capi. / Sales 2022 2,41x
Nbr of Employees 106
Free-Float 67,8%
Chart EAGLE PHARMACEUTICALS, INC.
Duration : Period :
Eagle Pharmaceuticals, Inc. Technical Analysis Chart | EGRX | US2697961082 | MarketScreener
Technical analysis trends EAGLE PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 52,29 $
Average target price 48,50 $
Spread / Average Target -7,25%
EPS Revisions
Managers and Directors
Scott L. Tarriff President, Chief Executive Officer & Director
Brian Cahill Chief Financial Officer
Michael Graves Chairman
Judith Ng-Cashin Chief Medical Officer & Executive Vice President
Michael Moran Executive VP, Chief Operating & Commercial Officer
Sector and Competitors